Cargando…

Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application

AIM OF THE STUDY: To establish and evaluate the fingerprint diagnostic models of cerebrospinal protein profile in glioma with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and bioinformatics analysis, in order to seek new tumor markers. MATERIAL AND MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jian, Yu, Jiekai, Shen, Hong, Zhang, Jianmin, Liu, Weiguo, Chen, Zhe, He, Shuda, Zheng, Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068817/
https://www.ncbi.nlm.nih.gov/pubmed/24966792
http://dx.doi.org/10.5114/wo.2014.40455
_version_ 1782322461543497728
author Liu, Jian
Yu, Jiekai
Shen, Hong
Zhang, Jianmin
Liu, Weiguo
Chen, Zhe
He, Shuda
Zheng, Shu
author_facet Liu, Jian
Yu, Jiekai
Shen, Hong
Zhang, Jianmin
Liu, Weiguo
Chen, Zhe
He, Shuda
Zheng, Shu
author_sort Liu, Jian
collection PubMed
description AIM OF THE STUDY: To establish and evaluate the fingerprint diagnostic models of cerebrospinal protein profile in glioma with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and bioinformatics analysis, in order to seek new tumor markers. MATERIAL AND METHODS: SELDI-TOF-MS was used to detect the cerebrospinal protein bond to ProteinChip H4. The cerebrospinal protein profiles were obtained and analyzed using the artificial neural network (ANN) method. Fingerprint diagnostic models of cerebrospinal protein profiles for distinguishing glioma from non-brain-tumor, and distinguishing glioma from benign brain tumor, were established. The support vector machine (SVM) algorithm was used for verification of established diagnostic models. The tumor markers were screened. RESULTS: In a fingerprint diagnostic model of cerebrospinal protein profiles for distinguishing glioma from non-brain tumor, the sensitivity and specificity of glioma diagnosis were 100% and 91.7%, respectively. Seven candidate tumor markers were obtained. In a fingerprint diagnostic model for distinguishing glioma from benign brain tumor, the sensitivity and specificity of glioma diagnosis were 88.9% and 100%, respectively, and 8 candidate tumor markers were gained. CONCLUSIONS: The combination of SELDI-TOF-MS and bioinformatics tools is a very effective method for screening and identifying new markers of glioma. The established diagnostic models have provided a new way for clinical diagnosis of glioma, especially for qualitative diagnosis.
format Online
Article
Text
id pubmed-4068817
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-40688172014-06-25 Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application Liu, Jian Yu, Jiekai Shen, Hong Zhang, Jianmin Liu, Weiguo Chen, Zhe He, Shuda Zheng, Shu Contemp Oncol (Pozn) Original Paper AIM OF THE STUDY: To establish and evaluate the fingerprint diagnostic models of cerebrospinal protein profile in glioma with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and bioinformatics analysis, in order to seek new tumor markers. MATERIAL AND METHODS: SELDI-TOF-MS was used to detect the cerebrospinal protein bond to ProteinChip H4. The cerebrospinal protein profiles were obtained and analyzed using the artificial neural network (ANN) method. Fingerprint diagnostic models of cerebrospinal protein profiles for distinguishing glioma from non-brain-tumor, and distinguishing glioma from benign brain tumor, were established. The support vector machine (SVM) algorithm was used for verification of established diagnostic models. The tumor markers were screened. RESULTS: In a fingerprint diagnostic model of cerebrospinal protein profiles for distinguishing glioma from non-brain tumor, the sensitivity and specificity of glioma diagnosis were 100% and 91.7%, respectively. Seven candidate tumor markers were obtained. In a fingerprint diagnostic model for distinguishing glioma from benign brain tumor, the sensitivity and specificity of glioma diagnosis were 88.9% and 100%, respectively, and 8 candidate tumor markers were gained. CONCLUSIONS: The combination of SELDI-TOF-MS and bioinformatics tools is a very effective method for screening and identifying new markers of glioma. The established diagnostic models have provided a new way for clinical diagnosis of glioma, especially for qualitative diagnosis. Termedia Publishing House 2014-06-03 2014 /pmc/articles/PMC4068817/ /pubmed/24966792 http://dx.doi.org/10.5114/wo.2014.40455 Text en Copyright © 2014 Termedia http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Paper
Liu, Jian
Yu, Jiekai
Shen, Hong
Zhang, Jianmin
Liu, Weiguo
Chen, Zhe
He, Shuda
Zheng, Shu
Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application
title Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application
title_full Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application
title_fullStr Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application
title_full_unstemmed Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application
title_short Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application
title_sort mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068817/
https://www.ncbi.nlm.nih.gov/pubmed/24966792
http://dx.doi.org/10.5114/wo.2014.40455
work_keys_str_mv AT liujian massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication
AT yujiekai massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication
AT shenhong massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication
AT zhangjianmin massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication
AT liuweiguo massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication
AT chenzhe massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication
AT heshuda massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication
AT zhengshu massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication